IFNA2 and neoplasm: The CD38-targeted attenuated IFNα fusion protein, or “AttenukineTM”, identified as anti-CD38-IFNα(att), displayed a 10,000-fold greater specificity than native IFNα for CD38-positive (tumor) vs CD38-negative (normal) cells (Fig 3C and 3D).